A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Eli Lilly and Company
Study ID
NCT01115803
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • LY2584702 — DRUG
    Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
  • Erlotinib — DRUG
    Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles. Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity.
  • Everolimus — DRUG
    Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.

Study Details

Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.

Key Dates

First listed
May 4, 2010
Start date
Mar 31, 2010
Status verified
Jan 2019
Primary completion
Jun 30, 2011
Completion
Jun 30, 2011

Study Design

Enrollment
29 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A: LY2584702 + Erlotinib
    Participants received 50 mg LY2584702 once daily (QD )+ 150 mg Erlotinib QD, 50 mg LY2584702 twice daily (BID) + 150 mg Erlotinib QD, 100 mg LY2584702 BID + 150 mg Erlotinib QD and 75 mg LY2584702 BID + 150 mg Erlotinib QD.
  • Experimental: Arm B: LY2584702 + Everolimus
    Participants received 50 mg LY2584702 QD + 10 mg Everolimus QD, 100 mg LY2584702 QD + 10 mg Everolimus QD and 50 mg LY2584702 BID + 10 mg Everolimus QD.

Primary Outcome Measure

Recommended Dose for Phase 2 Studies [ Time Frame: Baseline up to 6 cycles of 28 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.ChicagoIllinois60637-

Find similar trials in Chicago, IL

By condition
Neuroendocrine tumorsKidney cancer
By specialty
OncologyUrology
By research site
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Chicago, IL

Related Studies